Work

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.8559

Authors: Alexander Starodub, D. Ross Camidge, Ronald J. Scheff, Sajeve Samuel Thomas, Michael J. Guarino, Gregory A. Masters, Kevin Kalinsky, Leena Gandhi, Aditya Bardia, Wells A. Messersmith, Allyson J. Ocean, Pius P Maliakal, Robert M. Sharkey, Francois Wilhelm, David M Goldenberg, Rebecca Suk Heist

Institutions: Indiana University Health, Weill Cornell Medicine, University of Florida, Christiana Care Health System, Columbia University Irving Medical Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, University of Colorado Cancer Center, Immunomedics (United States)

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2522993687

Cites:

Cited by: 7

Related to: 10